Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer

• Published in: Tumori Vol. 97; no. 4; p. 466
• Main Authors: Yang, Tingsong, Shen, Xiaojun, Tang, Xiaojun, Wei, Guo, Zhang, Hao, Du, Chenghui, Xue, Xuchao, Ma, Liye, Nie, Mingming, Bi, Jianwei
• Format: Journal Article
• Language: English
• Published: United States 01.07.2011
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asian Continental Ancestry Group; Capecitabine; China; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Drug Administration Schedule; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Fluorouracil - analogs & derivatives; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Pilot Projects; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Survival Analysis; Treatment Outcome; China

The efficacy of chemotherapy for advanced gastric cancer is now widely accepted. However, the survival advantage is small, and no internationally accepted standard regimen has emerged. The present study investigated the efficacy and safety of oxaliplatin plus oral capecitabine (XELOX regimen) as fir...